Evidence suggests that caspase-2 deficiency protects mice from diet-induced obesity, metabolic syndrome, and non-alcoholic fatty liver disease, which has led to speculation that caspase-2 activity in NASH is beyond apoptosis. Here, CASP2 is linked to metabolic dysfunction-associated steatohepatitis.